Determination of Covid-19 antibodies after vaccination with a mRNA vaccine in peritoneal dialysis patients
Phase 1
- Conditions
- Chronic peritoneal dialysis patientsTherapeutic area: Diseases [C] - Immune System Diseases [C20]
- Registration Number
- EUCTR2021-002984-23-AT
- Lead Sponsor
- Medical University of Graz
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
18 to 90 years of age
End stage kidney disease patient undergoing peritoneal dialysis
Patient was scheduled to receive an approved SARS-CoV2 vaccine as part of their routinely performed care
Provided written informed consent for the Bio-Bank”
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 50
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 50
Exclusion Criteria
No informed consent of the Bio-Bank” was obtained
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method